Retatrutide, the Latest Weight Loss Peptidein 2023！

[Phcoker.com]

Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable medication is set for FDA approval. Retatrutide is in the same class as other weight loss drugs like Semaglutide and Tirzepatide.

However, what sets it apart from other obesity medications is that it targets three hunger-reducing hormones. Semaglutide only targets one hunger-controlling hormone called GLP-1, while Tirzepatide targets GLP-1 and GIP. Retatrutide takes it a notch higher by targeting three hunger-regulating hormones: GIP, GLP-1, and glucagon receptor.

 

[Phcoker.com]

Retatrutide weight loss facts ​

Phase II trial

In recent results from its Phase II trial (NCT04881760), data showed that after 48 weeks, in the retatrutide dosage 1mg, 4mg, 8mg, and 12mg groups, -8.7%, -17.1%, -22.8%, and -24.2% percentage change in body weight was recorded. Furthermore, a weight reduction of 15% or more was recorded in 60% of subjects in the study. With regards to safety, the most common adverse events were of a gastrointestinal nature, and thus retatrutide’s safety profile was on par with other incretin-based therapies.

And we can look forward to the effects of Phase III trial (TRIUMPH-3; NCT05882045).